Gemini Therapeutics, Inc. /DE: insider trades · United States · SEC (Form 4)

About Gemini Therapeutics, Inc. /DE

Gemini Therapeutics, Inc. /DE was a U.S.-based biopharmaceutical company that was historically listed on the NASDAQ before its merger with Disc Medicine. For French-, Belgian-, and Swiss-based investors, the key takeaway is that Gemini operated as a precision-medicine biotech, initially focused on genetically defined dry age-related macular degeneration (dry AMD) and, more broadly, on selected rare genetic diseases. The company was founded in 2015 and was headquartered in Cambridge, Massachusetts, United States, a leading life-science hub with a dense biotechnology ecosystem. ([crunchbase.com](https://www.crunchbase.com/organization/gemini-therapeutics?utm_source=openai)) Operationally, Gemini was more of a research-stage precision medicine platform than a mature commercial biotech. Its strategy was to map molecular abnormalities and genetic risk profiles to matched therapeutic modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. That approach was designed to differentiate the company in a competitive ophthalmology and rare-disease landscape where value creation depends heavily on scientific validation, clinical readouts, intellectual property, and the ability to translate biology into a viable development pipeline. ([cbinsights.com](https://www.cbinsights.com/company/gemini-therapeutics?utm_source=openai)) Gemini did not, to the best of available public information, have a broad commercial product portfolio at the time it operated independently; its investment case was primarily driven by its pipeline and by the clinical potential of its research programs. In August 2022, Gemini announced a merger agreement with Disc Medicine, another U.S. biopharmaceutical company focused on hematologic diseases and listed on NASDAQ. The transaction closed on December 29, 2022, and the combined company continued as Disc Medicine, trading under the ticker IRON on the NASDAQ Global Market. In practical terms, Gemini no longer exists as an independent publicly traded company. ([ir.discmedicine.com](https://ir.discmedicine.com/news-releases/news-release-details/gemini-therapeutics-and-disc-medicine-announce-merger-agreement?utm_source=openai)) From an investor-analysis perspective, current SEC references to Gemini should therefore be read as historical or transaction-related disclosures, including contingent value rights and merger-related filings. Gemini’s main relevance today is as a case study in early-stage ophthalmic genetics and precision therapeutics: a 2015-founded, Cambridge-based United States biotech that once traded on NASDAQ and was ultimately folded into Disc Medicine. ([crunchbase.com](https://www.crunchbase.com/organization/gemini-therapeutics?utm_source=openai))